NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis $2.97 +0.04 (+1.37%) Closing price 04:00 PM EasternExtended Trading$2.94 -0.03 (-0.84%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Adverum Biotechnologies Stock (NASDAQ:ADVM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADVM alerts:Sign Up Key Stats Today's Range$2.79▼$3.0550-Day Range$2.15▼$2.9752-Week Range$1.78▼$8.56Volume128,001 shsAverage Volume244,778 shsMarket Capitalization$62.31 millionP/E RatioN/ADividend YieldN/APrice Target$19.75Consensus RatingModerate Buy Company Overview Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Read More Adverum Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreADVM MarketRank™: Adverum Biotechnologies scored higher than 79% of companies evaluated by MarketBeat, and ranked 230th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAdverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 2 research reports in the past 90 days.Read more about Adverum Biotechnologies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Adverum Biotechnologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.13% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adverum Biotechnologies has recently decreased by 4.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.78 Percentage of Shares Shorted7.13% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adverum Biotechnologies has recently decreased by 4.24%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.30 News SentimentAdverum Biotechnologies has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Adverum Biotechnologies this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adverum Biotechnologies' insider trading history. Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADVM Stock News HeadlinesChardan Capital Has Pessimistic View of ADVM FY2025 EarningsAugust 19 at 2:35 AM | americanbankingnews.comHC Wainwright Brokers Increase Earnings Estimates for ADVMAugust 17, 2025 | americanbankingnews.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)Chardan Capital Reiterates "Buy" Rating for Adverum Biotechnologies (NASDAQ:ADVM)August 15, 2025 | americanbankingnews.comAdverum Biotechnologies sees cash runway into 4Q25August 12, 2025 | msn.comAdverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)August 12, 2025 | msn.comAdverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline HighlightsAugust 12, 2025 | globenewswire.comAdverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | globenewswire.comSee More Headlines ADVM Stock Analysis - Frequently Asked Questions How have ADVM shares performed this year? Adverum Biotechnologies' stock was trading at $4.67 at the beginning of 2025. Since then, ADVM shares have decreased by 36.4% and is now trading at $2.97. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) posted its earnings results on Tuesday, August, 12th. The biotechnology company reported ($2.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.24) by $0.10. When did Adverum Biotechnologies' stock split? Adverum Biotechnologies's stock reverse split before market open on Thursday, March 21st 2024.The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Adverum Biotechnologies' major shareholders? Adverum Biotechnologies' top institutional investors include BML Capital Management LLC (14.64%), Pale Fire Capital SE (1.72%), Geode Capital Management LLC (0.88%) and Jane Street Group LLC (0.34%). Insiders that own company stock include Braden Michael Leonard, Laurent Fischer, Peter Soparkar, Setareh Seyedkazemi, Brigit Riley, James Paul Scopa and Richard Beckman. View institutional ownership trends. How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/12/2025Today8/22/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADVM CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees190Year FoundedN/APrice Target and Rating Average Price Target for Adverum Biotechnologies$19.75 High Price Target$33.00 Low Price Target$4.00 Potential Upside/Downside+583.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($7.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.93 million Net MarginsN/A Pretax Margin-16,949.20% Return on Equity-297.29% Return on Assets-101.40% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.54 Sales & Book Value Annual Sales$1 million Price / Sales60.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.96) per share Price / Book-3.01Miscellaneous Outstanding Shares20,980,000Free Float19,725,000Market Cap$60.63 million OptionableOptionable Beta0.77 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ADVM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.